Access practice tools, as well as industry leading news, customizable alerts, dockets, and primary content, including a comprehensive collection of case law, dockets, and regulations. Leverage...
Nov. 9 — The maker of Nexium and Prilosec is likely to prevail on its claim that a generic drugmaker has infringed its trademark rights by selling a purple-colored heartburn pill, the U.S. District Court for the District of Delaware ruled Nov. 6.
Finding a likelihood of confusion and a likelihood of irreparable harm to the brand-name drug company, the court granted a temporary restraining order barring the generic maker from using purple capsules.
AstraZeneca AB makes Nexium and Prilosec, name-brand versions of the medication esomeprazole, which is used to treat stomach acid. Prilosec has been on the market since 1989, and Nexium was first sold in 2001.
The drugs are sold as purple-colored and capsules, and have been marketed under the name “The Purple Pill.”
In 2006, AstraZeneca received a U.S. trademark registration on the term “The Purple Pill” for gastrointestinal disease drugs (Registration No. 3188285). It also holds three registrations for purple and purple-and-gold-colored capsules for GI medications.
Nexium is also marketed through a website associated with the domain name purplepill.com.
AstraZeneca has licensed use of the “Nexium” name and the purple color trademark to Pfizer for an over-the-counter version, and has sued other generic drugmakers for using purple capsules for esomeprazole.
On Oct. 28, AstraZeneca brought a trademark infringement claim against Dr. Reddy's Laboratories Inc. for selling its generic esomeprazole in purple-colored capsules and moved for a preliminary injunction.
Even though Dr. Reddy's capsule was not exactly the same in appearance as the Nexium and Prilosec capsules—it was half dark purple and half light purple—the court found a likelihood of confusion.
AstraZeneca AB is a pharmaceutical company based in Sweden formed by the 1999 merger of Sweden's Astra AB and Britain's Zeneca Group PLC. Dr. Reddy's is an India-based maker of generic drugs founded in 1984.
The court's ruling was issued by Judge Sue L. Robinson.
AstraZeneca was represented by McCarter & English LLP, Wilmington, Del. Dr. Reddy's was represented by Smith, Katzenstein & Jenkins LLP, Wilmington.
To contact the reporter on this story: Anandashankar Mazumdar in Washington at email@example.com
To contact the editor responsible for this story: Mike Wilczek in Washington at firstname.lastname@example.org
Text is available at: http://src.bna.com/Y2.
All Bloomberg BNA treatises are available on standing order, which ensures you will always receive the most current edition of the book or supplement of the title you have ordered from Bloomberg BNA’s book division. As soon as a new supplement or edition is published (usually annually) for a title you’ve previously purchased and requested to be placed on standing order, we’ll ship it to you to review for 30 days without any obligation. During this period, you can either (a) honor the invoice and receive a 5% discount (in addition to any other discounts you may qualify for) off the then-current price of the update, plus shipping and handling or (b) return the book(s), in which case, your invoice will be cancelled upon receipt of the book(s). Call us for a prepaid UPS label for your return. It’s as simple and easy as that. Most importantly, standing orders mean you will never have to worry about the timeliness of the information you’re relying on. And, you may discontinue standing orders at any time by contacting us at 1.800.960.1220 or by sending an email to email@example.com.
Put me on standing order at a 5% discount off list price of all future updates, in addition to any other discounts I may quality for. (Returnable within 30 days.)
Notify me when updates are available (No standing order will be created).
This Bloomberg BNA report is available on standing order, which ensures you will all receive the latest edition. This report is updated annually and we will send you the latest edition once it has been published. By signing up for standing order you will never have to worry about the timeliness of the information you need. And, you may discontinue standing orders at any time by contacting us at 1.800.372.1033, option 5, or by sending us an email to firstname.lastname@example.org.
Put me on standing order
Notify me when new releases are available (no standing order will be created)